Premium
Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia
Author(s) -
Sorigue Marc,
Magnano Laura,
Miljkovic Milos D.,
NietoMoragas Javier,
SantosGomez Mireia,
Villamor Neus,
Junca Jordi,
MoralesIndiano Cristian
Publication year - 2020
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21849
Subject(s) - differential diagnosis , medicine , chronic lymphocytic leukemia , lymphoproliferative disorders , predictive value , mantle cell lymphoma , gastroenterology , leukemia , lymphoma , pathology , oncology
Background The role of CD200 in the differential diagnosis of chronic lymphocytic leukemia (CLL) and classical mantle cell lymphoma (MCL) is well established. Its role in the differential diagnosis of CLL and other lymphoproliferative disorders (LPD) is less clear, in particular its positive predictive value (PPV). Materials and methods We conducted a systematic review of the use of CD200 in the differential diagnosis of CLL, MCL, and other predominantly leukemic, typically CD103‐negative LPD. With the results, we then derived a curve to determine the PPV based on the prevalence of the disorders included in the differential diagnosis. Results Of 43 publications screened, 27 were included in the systematic review (5,764 patients). The median CD200 positivity rate in all studies and the percentage of CD200‐positive (pooled) patients was 100% and 95% (3,061/3,208) in CLL, 4 and 8% (86/1112) in MCL and 56 and 62% (425/689) in other LPD. Conclusion CD200 is suboptimal for the differential diagnosis of CLL and disorders other than nodal MCL.